Back to Journals » Therapeutics and Clinical Risk Management » Volume 13
Review
Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
11,943 | Dovepress* | 10,518+ | 1,741 | 12,259 | |
PubMed Central* | 1,425 | 497 | 1,922 | ||
Totals | 11,943 | 2,238 | 14,181 | ||
*Since 16 October 2017 |
Total mentioned | Delicious | Others | |||
---|---|---|---|---|---|
30 | 1 | 0 | 0 | 14 | 15 |
View citations on PubMed Central and Google Scholar